In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Analysts have recently evaluated Eli Lilly and Co and provided 12-month price targets. The average target is $930.96, accompanied by a high estimate of $1025.00 and a low estimate of $840.00.

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, ... Our analyst team just revealed what they believe are the 10 best stocks to buy right now.

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall within a range of $13.02 and $13.52 (the previous forecast was $16.10 to ...

Eli Lilly shares were 0.7% lower at $699.40 per share as of about 1:30 p.m. ET Tuesday. They have more than doubled in value over the past year amid the buzz surrounding its weight-loss drugs.

Chris Shibutani, an analyst from Goldman Sachs, maintained the Hold rating on Eli Lilly & Co (LLY – Research Report). The associated price target is $650.00. Geoff Meacham has given his Hold ...

Eli Lilly (NYSE:LLY) has been in the spotlight recently with a 3.96% share price increase over the past month. The selection ...

Eli Lilly forecasts $45 billion in 2024 revenue, a 32% growth but $400 million below Q3 guidance. Mounjaro and Zepbound expected to contribute $3.5 billion and $1.9 billion, respectively, to 2024 ...

(RTTNews) - While reporting financial results for the second quarter on Tuesday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year ...

Analysts have set 12-month price targets for Eli Lilly, revealing an average target of $964.46, a high estimate of $1125.00, and a low estimate of $884.00.

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 ...